Health News Releases

  • Today April 18
(Photo: Business Wire)
October 23, 2024 14:45
ANANDA Scientific and the David Geffen School of Medicine, UCLA, Announce Commencement of a Clinical Trial Evaluating Nantheia™ ATL5 for Smoking Cessation
ANANDA Scientific Inc. (https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fwww.anandascientific.com%2F&esheet=54138297&newsitemid=20241022571870&lan=en-US&anchor=ANANDA+Scientific+Inc.&
October 21, 2024 17:20
ASDS 2024: New Phase III READY-4 Data Demonstrate Long-Term Safety and Efficacy of Galderma’s RelabotulinumtoxinA (Relfydess™)
Galderma today announced new phase III data from the READY-4 clinical trial, demonstrating the long-term safety of RelabotulinumtoxinA (Relfydess™) for frown lines and crow’s feet after repeated injec
October 18, 2024 11:35
Medidata Announces Rave Lite to Support Growth in Early and Late-Stage Clinical Trials
Medidata (https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fwww.medidata.com%2Fen%2F&esheet=54136391&newsitemid=20241017355667&lan=en-US&anchor=Medidata&index=1&md5=d87912bb1e54e36a39a
Measuring 35x35cm, the material has been produced using the company’s newly scaled-up tissue bioreac
October 17, 2024 14:45
Bio-Engineering Scale-Up Qorium Showcases Cultivated Leather Breakthrough, Signalling a Key Step Towards Commercialisation
Cultivated leather pioneer Qorium has released footage (https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fvimeo.com%2F1017020585%3Fshare%3Dcopy%23t%3D0&esheet=54135213&newsitemid=20241
(Photo: Business Wire)
October 17, 2024 14:30
ANANDA Scientific Announces a Clinical Trial Evaluating Nantheia™ ATL5, in the treatment of Co-Occurring Opioid Use Disorder and Chronic Pain
ANANDA (https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fanandascientific.com%2F&esheet=54135042&newsitemid=20241015941899&lan=en-US&anchor=ANANDA&index=1&md5=44a7f5c1680156e5b97b89ec
Top 10 finalist nurses for Aster Guardians Global Nursing Award 2024 (Photo: AETOSWire)
October 17, 2024 14:25
Aster Guardians Global Nursing Award Announces Top 10 Finalists for 2024
Aster Guardians Global Nursing Award has today unveiled the top 10 finalists for 2024, one of whom will go on to win the grand title award of US $ 250,000. These 10 nurses have been shortlisted from a
October 14, 2024 16:00
Dong-A ST’s IMULDOSA™ (ustekinumab-srlf), a Biosimilar to STELARA®, receives approval from US FDA
Dong-A ST (http://en.donga-st.com/Main.da) (President/CEO Jae-Hun Jung, KRX: 170900) announced on October 11 that Imuldosa™ (usteki-numab-srlf/DMB-3115), a biosimilar referencing Stelara®, has won U.S
Avania, the leading, global medical technology contract research organization and advisory services
October 09, 2024 14:10
Avania Buys Spanish MedTech CRO Anagram to Enhance Its Core CRO Offering in a New European Geography
Avania (https://www.avaniaclinical.com/), the leading, global medical technology contract research organization (CRO) and advisory services partner, today announced its acquisition of Anagram (https:/
October 09, 2024 12:25
EU Notified Body (BSI Netherlands) and the EMA Grant Approval of the LeukoStrat® CDx FLT3 Mutation Assay for VANFLYTA® Therapy in the EU and EEA
Invivoscribe is excited to announce that their CE-2797 IVD certified LeukoStrat® CDx FLT3 Mutation Assay has been approved by BSI (Netherlands) and the EMA to aid in the selection of individuals in th
A radiologist looking at MRI exam images (Photo: Business Wire)
October 08, 2024 08:37
GE HealthCare Announces Phase I Results for a First-of-its-Kind Macrocyclic Manganese-Based MRI Contrast Agent
GE HealthCare (Nasdaq: GEHC) has today announced the completion of its Phase I clinical development program for a first-of-its-kind manganese-based macrocyclic magnetic resonance imaging (MRI) contras
October 04, 2024 16:50
Ferring Pharmaceuticals bolsters global gene therapy supply chain with European manufacturing facility
Ferring Pharmaceuticals today announced the opening of a state-of-the-art global manufacturing hub in Finland for the drug substance of its intravesical non-replicating gene therapy Adstiladrin® (nado
October 02, 2024 13:45
Crown Bioscience Expands Singapore Facility with Advanced Oncology Models and Imaging Capabilities
Crown Bioscience (https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fwww.crownbio.com%2F&esheet=54128719&newsitemid=20241001076209&lan=en-US&anchor=Crown+Bioscience&index=1&md5=d0a4aa1a
AOP Health CEO Martin Steinhart (Copyright: AOP Health/Studio Koekart)
October 02, 2024 13:45
Cancer Therapy: AOP Health Investigates a New Approach Targeting Cancer Stem Cells
AOP Orphan Pharmaceuticals GmbH (AOP Health) in collaboration with Leukos Biotech has achieved a key milestone. The first patient was included in the phase I clinical trial SERONCO-1, in which a subst
October 02, 2024 09:42
Ferring Demonstrates Effectiveness of a Treat-to-Target Approach in Mild-to-Moderate Ulcerative Colitis in First Major Study
Ferring Pharmaceuticals today announces results from the OPTIMISE study showing the first real-world evidence of the effectiveness of a treat-to-target (T2T) approach based on faecal calprotectin (FC)
Novotech is a Great Place to Work Certified in the USA (Graphic: Business Wire)
October 01, 2024 15:25
Novotech Earns Great Place to Work® Certification in the United States
Novotech, a global full-service clinical Contract Research Organization (CRO), is proud to announce that it has been certified as a Great Place to Work® in the United States. This award reflects Novot
October 01, 2024 11:20
SK pharmteco Invests $260 Million to Expand Global Small Molecule and Peptide Production
SK pharmteco, a global contract development and manufacturing organization (CDMO), today announced a major expansion of its small molecule and peptide production capabilities with a $260 million inves
September 27, 2024 14:19
Global Oncology Innovator BeiGene Appoints Shalini Sharp to Board of Directors
BeiGene (https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fwww.beigene.com%2F&esheet=54127370&newsitemid=20240926501587&lan=en-US&anchor=BeiGene&index=1&md5=35ef0ca3f29c557d3fdea29b228
Logo
September 26, 2024 16:40
Merz Aesthetics Announces the Launch of Ultherapy PRIME Platform as the Next Generation of Nonsurgical Skin Lifting Treatments
Merz Aesthetics, the world’s largest dedicated medical aesthetics business, announced today the launch of Ultherapy PRIME - a noninvasive, FDA-cleared medical aesthetics treatment that provides a trul
PCI Pharma Services is investing more than $365 million in infrastructure supporting the clinical an
September 26, 2024 14:25
PCI Pharma Services Invests Over $365 Million in EU, US Facilities for Clinical and Commercial Supply of Advanced Drug Delivery and Drug-Device Combination Products
PCI Pharma Services, (“PCI”) a leading global contract development and manufacturing organization (CDMO) focused on biopharma’s most complex therapies, is investing more than $365 million in infrastru
September 26, 2024 11:15
Medidata Extends Its Commitment to the Patient Experience with the Launch of Patient Payments
Medidata (https://cts.businesswire.com/ct/CT?id=smartlink&url=http%3A%2F%2Fwww.medidata.com&esheet=54126085&newsitemid=20240925388965&lan=en-US&anchor=Medidata&index=1&md5=2a7f1d88d61b0fe6c85a6c34c7cb
September 26, 2024 10:50
Fujirebio Submits FDA Regulatory Filing for Lumipulse® G pTau 217/β-Amyloid 1-42 Plasma Ratio In-Vitro Diagnostic Test as an Aid to Identify Patients With Amyloid Pathology Associated With Alzheimer’s Disease
Fujirebio today announced that its wholly-owned subsidiary Fujirebio Diagnostics, Inc. has filed its Lumipulse® G pTau 217/β-Amyloid 1-42 Plasma Ratio in-vitro diagnostic (IVD) test with the U.S. Food
September 25, 2024 15:25
Rigaku Holdings Corporation: Approval of Listing on the Tokyo Stock Exchange Prime Market
Rigaku Holdings Corporation, a global solution partner for X-ray analysis (headquarters: Akishima, Tokyo; president and CEO: Jun Kawakami; “Rigaku”), has been approved for a new listing of its shares
September 25, 2024 14:37
EADV 2024 Late Breaking News Sessions: New Galderma Data Demonstrating Nemolizumab’s Long-term Efficacy and Safety in Atopic Dermatitis and Durability in Prurigo Nodularis to Be Shared During Three Oral Presentations
Galderma today announced that it will present new data from the ARCADIA and OLYMPIA clinical trial programs investigating nemolizumab in atopic dermatitis and prurigo nodularis, respectively, at the 2
September 25, 2024 14:10
Aurion Biotech Launches Vyznova® (neltependocel) in Japan for the Treatment of Bullous Keratopathy of the Cornea
Aurion Biotech (https://cts.businesswire.com/ct/CT?id=smartlink&url=http%3A%2F%2Fwww.aurionbiotech.com%2F&esheet=54125897&newsitemid=20240924085009&lan=en-US&anchor=Aurion+Biotech&index=1&md5=0d280e30
September 25, 2024 09:03
Takeda Receives Approval for FRUZAQLA (fruquintinib) in Japan for the Treatment of Unresectable Advanced or Recurrent Colorectal Cancer
Takeda (TSE:4502/NYSE:TAK (https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fwww.takeda.com%2Finvestors%2F&esheet=54124287&newsitemid=20240918509211&lan=en-US&anchor=TSE%3A4502%2FNYSE%
25 per page50 per page75 per page100 per page